LRRK2 and Parkinson disease: Some experiments have addressed the locus-specific CpG methylation status of mutant α-Syn in lymphoblastoid cells, or investigated the epigenome-wide impacts of other PD-associated mutations, such as LRRK2 G2019S, in PD patient-derived induced pluripotent stem cells (iPSCs) (Voutsinas et al., 2010; Fernández-Santiago et al., 2015, 2019).